Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
05 February 2021Website:
http://www.vorbio.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 20:11:55 GMTDividend
Analysts recommendations
Institutional Ownership
VOR Latest News
Vor Biopharma (VOR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Vor Bio (VOR) stock gains after dosing the first patient in its phase I/II study of novel cell therapy, VCAR33 (Allogenic), to treat AML. The company extends its cash runway into the second half of 2025.
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
The mean of analysts' price targets for Vor Biopharma Inc. (VOR) points to a 172.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Vor Biopharma Inc. is the brainchild of Dr. Siddhartha Mukherjee. Its core idea is to make CAR-Ts safer by using stem cells.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, reported its financial results for the three-month period and full year that ended December 31, 2022, and provided a business update. The post Vor Bio Announces Q4 And FY 2022 Results appeared first on Pulse 2.0.
What type of business is Vor Biopharma?
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What sector is Vor Biopharma in?
Vor Biopharma is in the Healthcare sector
What industry is Vor Biopharma in?
Vor Biopharma is in the Biotechnology industry
What country is Vor Biopharma from?
Vor Biopharma is headquartered in United States
When did Vor Biopharma go public?
Vor Biopharma initial public offering (IPO) was on 05 February 2021
What is Vor Biopharma website?
https://www.vorbio.com
Is Vor Biopharma in the S&P 500?
No, Vor Biopharma is not included in the S&P 500 index
Is Vor Biopharma in the NASDAQ 100?
No, Vor Biopharma is not included in the NASDAQ 100 index
Is Vor Biopharma in the Dow Jones?
No, Vor Biopharma is not included in the Dow Jones index
When does Vor Biopharma report earnings?
The next expected earnings date for Vor Biopharma is 09 August 2024